Medigus Announces First MUSE(TM) Procedure for the Treatment of GERD Performed in Israel at Shaare-Zedek Medical Center
December 27 2017 - 7:00AM
Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company
developing minimally invasive endosurgical tools and an innovator
in direct visualization technology, today announced the completion
of the first MUSE procedure in Israel. The procedure was performed
by Dr. Wengrower, Head, Therapeutic Endoscopy Unit, and his
colleagues Dr. Paz and Dr. Livovsky at the Digestive Diseases
Institute, Shaare-Zedek Medical Center. Dr. Wengrower reported that
the patient who had undergone the procedure felt minimal discomfort
during the procedure, and was released from the hospital after two
days, with no complications.
The MUSE system is a single-use flexible transoral stapler that
merges the latest advancement in microvisual, ultrasonic and
surgical stapling. The device comes equipped with an ultrasonic
sight and range finder and a micro ScoutCam™ CMOS camera, which
enables a single physician to perform an incisionless transoral
fundoplication, the procedure intended to treat the anatomical
cause of gastroesophageal reflux disease (GERD). As the device
requires no incisions, patients generally report greater comfort
during the procedure and experience reduced hospital stays by up to
50% over invasive fundoplication procedures.
“With up to twelve and a half percent of the adult Israeli
population experiencing GERD symptoms on a weekly basis1, I am
excited to help bring the MUSE system to Israel to reduce the need
for pharmaceuticals and invasive surgical procedures for the
treatment of GERD,” said Dr. Wengrower. “The incision-less
procedure reduces surgery time and hospital stays, offering an
attractive alternative to current GERD treatments.”
Those who experience symptoms such as heartburn or regurgitation
twice a week or more, may be at risk for persistent GERD.
About Medigus
Medigus is a medical device company specializing in developing
minimally invasive endosurgical tools and highly innovative imaging
solutions. Medigus is the developer of the MUSE™ system, an FDA
cleared and CE marked endoscopic device to perform Transoral
Fundoplication (TF) for the treatment of GERD (gastroesophageal
reflux disease), one of the most common chronic conditions in the
world. In 2016, the CMS established the Category I CPT® Code of
43210 for TF procedures, such as the ones performed with MUSE,
which establishes reimbursement values for physicians and
hospitals. MUSE is gaining adoption in key markets around the world
– it is available in world-leading healthcare institutions in the
U.S., Europe and Israel. Medigus is also in the process of
obtaining regulatory clearance in China. Medigus is traded on the
Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To
learn more about the company’s advanced technology, please visit
www.medigus.com or www.RefluxHelp.com.
This press release may contain statements that are
“Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of the company’s management
and its knowledge of the relevant market. The company has tried,
where possible, to identify such information and statements by
using words such as “anticipate,” “believe,” “envision,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” “contemplate” and other similar expressions
and derivations thereof in connection with any discussion of future
events, trends or prospects or future operating or financial
performance, although not all forward-looking statements contain
these identifying words. These forward-looking statements
represent Medigus’ expectations or beliefs concerning future
events, and it is possible that the results described in this press
release will not be achieved. By their nature, Forward-Looking
Statements involve known and unknown risks, uncertainties and other
factors which may cause future results of the company’s activity to
differ significantly from the content and implications of such
statements. Other risk factors affecting the company are discussed
in detail in the Company's filings with the Securities and Exchange
Commission. Forward-Looking Statements are pertinent only as of the
date on which they are made, and the company undertakes no
obligation to update or revise any Forward-Looking Statements,
whether as a result of new information, future developments or
otherwise. Neither the company nor its shareholders, officers and
employees, shall be liable for any action and the results of any
action taken by any person based on the information contained
herein, including without limitation the purchase or sale of
company securities. Nothing in this press release should be deemed
to be medical or other advice of any kind.
1 Moshkowitz M, Horowitz N, Halpern Z, Santo E. Gastroesophageal
reflux disease symptoms: prevalence, sociodemographics and
treatment patterns in the adult Israeli population. World J
Gastroenterol. 2011;17(10):1332-1335.
doi:10.3748/wjg.v17.i10.1332.
MEDIA CONTACT:
Chantal Beaudry
Lazar Partners Ltd.
212-867-1762
cbeaudry@lazarpartners.com
INVESTOR RELATIONS (Israel):
Iris Lubitch/ Noam Yellin
SmarTeam
972-3-6954333
Iris@Smartteam.co.il
Noam@Smartteam.co.il
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024